Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Total liabilities của Vertex Pharmaceuticals: $7,175M trong Q2 2026, tăng 4.6% so với cùng kỳ năm trước.
Mới nhất, Q2 2026
7,175
Kỳ kết thúc Jun 30, 2026
Thay đổi so với cùng kỳ năm trước
+4.6%
6,861 trong Q2 2025
Lịch sử
67 quý
Từ Q4 2009
Nguồn
64
Các tài liệu được dẫn bên dưới
Số của Q2 2026 lấy từ đâu
Nguồn: Form 10-Q (filed 2026-08-04) ↗
Được báo cáo trong Form 10-Q / 10-K (DB).
Lịch sử theo quý
Rê chuột vào một số để xem câu chữ đã đọc ra số đó; số tự tính sẽ hiện công thức
| Kỳ | Kết thúc | Total liabilities ($M) ($M) | So với cùng kỳ | Nguồn |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7,175 | +4.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 7,123 | +11.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 6,977 | +13.9% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 7,544 | +14.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 6,861 | +28.1% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 6,384 | +18.9% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,124 | +18.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 6,609 | +26.8% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,357 | +9.8% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,371 | +18.3% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,150 | +21.5% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,213 | +41.8% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 4,879 | +33.7% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 4,542 | +35.6% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,238 | +27.2% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,677 | +19.1% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,649 | +20.6% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,349 | +6.8% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,333 | +8.7% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,088 | -2.5% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,025 | +12.2% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,135 | +28.9% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 3,065 | +37.2% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 3,168 | +40.1% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 2,697 | +37.4% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,432 | +33.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,233 | +23.3% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,261 | +34.1% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,964 | +21.2% | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,820 | +19.6% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,811 | +20.4% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,686 | +20.9% | Form 10-Q (filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,621 | +14.2% | Form 10-Q (filed 2018-07-26) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,522 | +20.4% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,504 | -3.5% | Form 10-K (filed 2018-02-15) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,395 | -0.4% | Form 10-Q (filed 2017-10-30) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,418 | +2.8% | Form 10-Q (filed 2017-07-28) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,264 | -7.9% | Form 10-Q (filed 2017-04-28) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,559 | +10.9% | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,401 | +3.2% | Form 10-Q (filed 2016-10-31) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,380 | +4.1% | Form 10-Q (filed 2016-08-01) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,372 | +17.4% | Form 10-Q (filed 2016-05-03) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,405 | +13.4% | Form 10-Q (filed 2016-05-03) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,357 | +8.6% | Form 10-Q (filed 2015-10-30) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,326 | +40.2% | Form 10-Q (filed 2015-08-04) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,168 | +20.9% | Form 10-Q (filed 2015-05-04) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,239 | +28.7% | Form 10-K (filed 2015-02-13) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,250 | +14.1% | Form 10-Q (filed 2014-11-06) ↗ |
| Q2 2014 | Jun 30, 2014 | 946 | -8.7% | Form 10-Q (filed 2014-07-31) ↗ |
| Q1 2014 | Mar 31, 2014 | 966 | -31.7% | Form 10-Q (filed 2014-05-05) ↗ |
| Q4 2013 | Dec 31, 2013 | 963 | -36.9% | Form 10-K (filed 2014-02-11) ↗ |
| Q3 2013 | Sep 30, 2013 | 1,096 | -24.6% | Form 10-Q (filed 2013-11-07) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,036 | -23.9% | Form 10-Q (filed 2013-08-02) ↗ |
| Q1 2013 | Mar 31, 2013 | 1,415 | +14.1% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,525 | +23.1% | Form 10-K (filed 2013-03-01) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,454 | +6.8% | Form 10-Q (filed 2012-11-06) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,361 | +3.6% | Form 10-Q (filed 2012-08-08) ↗ |
| Q1 2012 | Mar 31, 2012 | 1,240 | +8.2% | Form 10-Q (filed 2012-05-10) ↗ |
| Q4 2011 | Dec 31, 2011 | 1,239 | +1.4% | Form 10-K (filed 2012-02-22) ↗ |
| Q3 2011 | Sep 30, 2011 | 1,361 | +9.9% | Form 10-Q (filed 2011-11-03) ↗ |
| Q2 2011 | Jun 30, 2011 | 1,314 | +58.9% | Form 10-Q (filed 2011-08-09) ↗ |
| Q1 2011 | Mar 31, 2011 | 1,147 | +47.1% | Form 10-Q (filed 2011-05-06) ↗ |
| Q4 2010 | Dec 31, 2010 | 1,222 | +42.2% | Form 10-K (filed 2011-02-17) ↗ |
| Q3 2010 | Sep 30, 2010 | 1,239 | – | Form 10-Q (filed 2010-10-28) ↗ |
| Q2 2010 | Jun 30, 2010 | 827 | – | Form 10-Q (filed 2010-08-03) ↗ |
| Q1 2010 | Mar 31, 2010 | 780 | – | Form 10-Q (filed 2010-05-03) ↗ |
| Q4 2009 | Dec 31, 2009 | 859 | – | Form 10-Q (filed 2010-05-03) ↗ |
Trích dẫn dữ liệu này
StockData. (2026). Total liabilities ($M) của Vertex Pharmaceuticals, theo quý Q4 2009–Q2 2026 [Bộ dữ liệu]. Tổng hợp từ Hồ sơ SEC và tài liệu dành cho nhà đầu tư của Vertex Pharmaceuticals. https://stockdatahq.com/stocks/vrtx/kpis/fs-tl
Xem mọi chỉ số ở bảng KPI của Vertex Pharmaceuticals. Dữ liệu cập nhật Nov 2, 2026.
See a number that looks wrong?